StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research report sent to investors on Sunday. The brokerage issued a sell rating on the stock.
Separately, Maxim Group lowered their price target on Moleculin Biotech from $20.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, November 12th.
Check Out Our Latest Stock Report on Moleculin Biotech
Moleculin Biotech Stock Down 27.9 %
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Recommended Stories
- Five stocks we like better than Moleculin Biotech
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- How is Compound Interest Calculated?
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- What Are Growth Stocks and Investing in Them
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
